The NGF System and its interplay with endocannabinoid signalling, from peripheral sensory terminals to the brain: new targets for the development of next generation drugs for neuropathic pain

Innovation House
Discovery Park
Ramsgate Road
Kent – United Kingdom

  • Institute Presentation

    Levicept is a privately owned spin-off company, formed following the closure of Pfizer’s Research and Development campus at Sandwich Kent UK. Levicept’s focus is the discovery and development of novel biological therapies for the treatment of pain. Levicept is currently developing the novel neurotrophic scavengingmolecule p75-Fc, for the treatment of neuropathic and inflammatory pain.

  • Project Staff


    Simon Westbrook

    CEO at Levicept Ltd

    Simon Westbrook previously worked at Pfizer Sandwich (1996-2011) discovering novel therapies for the treatment of pain, metabolic diseases and urology. Following the closure of Pfizer Sandwich, Simon established two spin-out companies focusingon the discovery and development of novel therapies for the treatment of pain and fibrotic diseases. Whilst at Pfizer Simon lead a group of exploratory pain scientists who discovered a number of novel treatments for pain of which TrkA inhibitors have recently entered clinical trials. Simon Westbrook is the CEO of Levicept and inventor of the p75-Fc patent for the treatment of pain. Simon is the named inventor of over 25 patents.